



Sheet 1 of 1

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2700-1-001N
		SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	David Nanus
		FILING DATE	March 16, 2001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
KAC	CL	WO 96/04891	2-22-96	PCT			
✓	CM	WO 93/13751	7-22-93	PCT			
✓	CN	WO 89/06977	8-10-99	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	CO	Paulo et al., J. Pharm. Clin.; 18:318-20 (1999)
KAC	CP	Marth et al., Int. J. Cancer; 40:840-845 (1987)
KAC	CQ	Pagnan et al., Journal of Liposome Research; 8:401-423 (1998)
KAC	CR	Pagnan et al., Int. J. Cancer; 81:268-274 (1999)
✓	GS	Regazzi et al., Clin Pharmacokinet; 32:382-402 (1997) <i>duplicate of 892</i>

2/10/04

EXAMINER: <i>Karen A. Gamble</i>	DATE CONSIDERED: <i>1/23/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2700-1-001N
		SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	David Nanus
		FILING DATE	March 16, 2001
		GROUP	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

JUN 18 2003

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

RECEIVED

JUN 18 2003

ECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC ✓	AT	Adamson et al., J Clin Oncol., 15:3330-7 (1997)
✓	AU	Arbaje et al., Journal of Interferon Research, 13:25-32 (1993)
✓	AV	Arnold et al., J Natl Cancer Inst., 86:306-9 (1994)
✓	AW	Athanasiadis et al., Clin Cancer Res., 1:973-9 (1995)
✓	AX	Atzpodien et al., World J Urol, 13:174-177 (1995)
✓	AY	Bollag et al., in <u>Retinoids in Oncology</u> , W.K. Hong and R. Lotan (eds), Chapter 4, pages 89-108 (1993)
✓	AZ	Bonhomme-Faivre et al., International Journal of Pharmaceutics, 134:99-104 (1996)
✓	BA	Brembeck et al., Cancer, 83:2317-23 (1998)
✓	BB	Casali et al., J Exp Clin Cancer Res., 17:227-9 (1998)
✓	BC	Cascinu et al., Ann Oncol., 7:538-9 (1996)

EXAMINER: <i>John A. Farrelly</i>	DATE CONSIDERED: <i>4/23/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 2700-1-001N
		SERIAL NO. 09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT David Nanus
		FILING DATE March 16, 2001
		GROUP 1642

KAL	✓	BD	Dhingra et al., Invest New Drugs, 11:39-43 (1993)
	✓	BE	Eisenhauer et al., Leukemia, 8:1622-5 (1994)
	✓	BF	Escudier et al., J Immunother, 21:62-4 (1998)
	✓	BG	Fierbeck et al., Cancer Immunol Immunother., 40:157-64 (1995)
	✓	BH	Frey et al., Cancer Letters, 57:223-227 (1991)
	✓	BI	Hallum et al., Gynecol Oncol., 56:382-6 (1995)
	✓	BJ	Handa et al., Leukemia Res., 21:1087-96 (1997)
	✓	BK	Hoffmann et al., Int J Cancer, 70:475-7 (1997)
	✓	BK	Knobler et al., J Am Acad Dermatol, 24:247-52 (1991)
	✓	BL	Kok et al., Eur J Cancer, 33:165-6 (1997)
	✓	BM	Kudelka et al., Anti-Cancer Drugs, 4:335-7 (1993)
	✓	BN	Lindner et al., Clin Cancer Res., 3:931-7 (1997)
	✓	BO	Lingen et al., Cancer Res., 58:5551-8 (1998)
	✓	BP	Lippman et al., J Natl Cancer Inst., 85:499-500 (1993)
	✓	BQ	Lippman et al., J Natl Cancer Inst., 84:235-241 (1992)
	✓	BR	Lippman et al., J Natl Cancer Inst., 84:241-245 (1992)
	✓	BS	Marth et al., JNCL, 77:1197-1202 (1986)
	✓	BT	Matarrese et al., Int. J. Cancer, 76:531-40 (1998)

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

EXAMINER: <i>John J. Guille</i>	DATE CONSIDERED: <i>11/23/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2700-1-001N
		SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	David Nanus
		FILING DATE	March 16, 2001
		GROUP	1642

✓ BU	Moore et al., Semin Hematol., 31(4, Suppl 5):31-7 (1994)
✓ BV	Moore et al., Am J Clin Oncol., 18:525-7 (1995)
✓ BW	Nikolaou et al., J Laryngol Otol., 110:857-61 (1996)
✓ BX	Pazdur et al., Am J Clin Oncol., 18:436-8 (1995)
✓ BY	Rinaldi et al., Anti-Cancer Drugs, 4:33-6 (1993)
✓ BZ	Rosenthal et al., Am J Clin Oncol., 21:352-4 (1998)
✓ CA	Roth et al., Oncology, 51:84-6 (1994)
✓ CB	Slabber et al., Invest New Drugs., 14:391-4 (1996)
✓ CC	Sondak et al., Cancer J Sci Am., 5:41-7 (1999)
✓ CD	Spieth et al., Arch Derm, 135:1035-1037 (1999)
✓ CE	Toma et al., Int J Cancer, 70:491-3 (1997)
✓ CF	Toma et al., Ann Oncol., 5:463-5 (1994)
✓ CG	Toma et al., Anticancer Res., 16:931-6 (1996)
✓ CH	Triozzi et al., Cancer Invest., 14:293-8 (1996)
CI	Voravud et al., Invest New Drugs, 11:57-60 (1993)
CJ	Wadler et al., Cancer, 79:1574-1580 (1997)
CK	Weiss et al., Gynecologic Oncology, 71:386-390 (1998)

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

EXAMINER: <i>John A. Gamble</i>	DATE CONSIDERED: <i>11/23/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	